Saturday, July 11, 2026

pharma · Neurological Autoimmune Diseases

Juventas Cell Therapy

Juventas Cell Therapy is a pharma organization headquartered in CN. Primary therapeutic focus areas include Neurological Autoimmune Diseases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent re

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
1
Patents
0

Quick answer

Juventas Cell Therapy is a pharma organization headquartered in CN. Primary therapeutic focus areas include Neurological Autoimmune Diseases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1).

Company snapshot

Juventas Cell Therapy is a pharma organization headquartered in CN. Primary therapeutic focus areas include Neurological Autoimmune Diseases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1).

  • 1 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Juventas Cell Therapy. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum signals

Momentum

Proprietary activity score for Juventas Cell Therapy.

1 active signal

7 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 1 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Recent activity

Latest pipeline, patent, and corporate events for Juventas Cell Therapy.

  1. Clinical update

    CNCT19 cell injection — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Juventas Cell Therapy?

    Juventas Cell Therapy is a pharma organization headquartered in CN. Primary therapeutic focus areas include Neurological Autoimmune Diseases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.

  • Is Juventas Cell Therapy publicly traded?

    Juventas Cell Therapy appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Juventas Cell Therapy develop or market?

    We link 1 drug profile(s) where Juventas Cell Therapy is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/juventas-cell-therapy#company-drugs.

  • What are the latest developments for Juventas Cell Therapy?

    In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Juventas Cell Therapy focus on?

    Juventas Cell Therapy focuses on Neurological Autoimmune Diseases based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Immunology
2